Heterologous Prime/Boost Immunization with p53-based Vaccines Combined with Toll-Like Receptor Stimulation Enhances Tumor Regression

The p53 gene product is overexpressed in ~50% of cancers, making it an ideal target for cancer immunotherapy. We previously demonstrated that a modified vaccinia Ankara (MVA) vaccine expressing human p53 (MVA-p53) was moderately active when given as a homologous prime/boost in a human p53 knock in (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ishizaki, Hidenobu, Song, Guang-Yun, Srivastava, Tumul, Carroll, Kyla Driscoll, Shahabi, Vafa, Manuel, Edwin R., Diamond, Don J., Ellenhorn, Joshua D.I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523364/
https://ncbi.nlm.nih.gov/pubmed/20551836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181e032c6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados